As the need for large-volume delivery grows, so does the need to standardize primary containers in the OBDS world. As such, we know that we must partner transparently and seamlessly with members of the ‘primary container ecosystem’ to help define the standard.

Grand River Aseptic Manufacturing and LTS Device Technologies understand the paradoxical need for standardization and flexibility. Yet, we ask ourselves, is the standardization of large-volume primary containers and components on the horizon?

The innovator drug products above 5 mL are coming, and several on-body-based drug products will lose exclusivity over the coming 2-10 years. Subsequent biosimilar launches will rely heavily on large volume OBDS to maintain or exceed the patient experience of the innovator product. With impending demand, we can’t sit around and wait for the world to tell us what standard is, so we must create it.

You will leave the session with an understanding of: 

• The criticality of CDMOs and drug delivery device innovators collaborating
• The benefits of standardized offerings of large-volume primary containers and components 
• How to eliminate extra investments and timeline extensions for unique primary containers 
• And more!

Speakers: